Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.
Eggs are lean protein and appeal to people taking Ozempic, Wegovy, or other GLP-1 medications. But a big spike in prices has ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback